KRAS G12C inhibitors show clinical success, but resistance and co-mutation context limit durable benefit

◇ RESEARCH

A review of KRAS-mutant cancers notes that covalent KRAS G12C inhibitors have transformed a historically "undruggable" target into a tractable therapeutic class, though durable benefit remains limited by adaptive feedback, acquired resistance, and tumor-lineage-specific barriers. (MedComm)